Sanofi, Schrödinger ink $120M drug design pact
Schrödinger, a global provider of advanced molecular simulations and enterprise software solutions and services for life sciences and materials research, has entered into a collaboration with Sanofi in which Schrödinger will provide comprehensive computational drug design support, from target analysis and validation to lead identification and lead optimization, for as many as ten drug discovery programs. Schrödinger could receive up to $120 million under the terms of the broad, multi-year relationship that includes preclinical milestones.
Schrödinger has made a number of key scientific breakthroughs in recent years in the areas of protein and ligand structure determination and potency prediction that promise to have a transformative impact on the discovery of drugs. The collaboration with Sanofi aims to deploy this and related technologies in the pharmaceutical industry. In addition, a new enterprise informatics system to facilitate real-time collaboration between computational designers and medicinal chemists will serve as the communications and project management platform for researchers across both companies.